



EDINBURGH WORLDWIDE INVESTMENT TRUST plc

Growth companies
shaping our tomorrow



Interim Financial Report
30 April 2018





Objective

Edinburgh Worldwide's objective is the achievement of long term capital growth by investing primarily in listed companies throughout the world.

Comparative Index

The index against which performance is compared is the S&P Global Small Cap Index total return (in sterling terms). Prior to 1 February 2014 the comparative index was the MSCI All Countries World Index (in sterling terms). For periods commencing prior to this date, the returns on these indices for their respective periods are linked together to form a single comparative index.

Principal Risks and Uncertainties

The principal risks facing the Company are financial risk, investment strategy risk, discount risk, regulatory risk, custody and depositary risk, small company risk, unlisted investments, operational risk, leverage risk and political and associated economic risk. An explanation of these risks and how they are managed is set out on pages 7 and 8 of the Company's Annual Report and Financial Statements for the year to 31 October 2017 which is available on the Company's website:

www.edinburghworldwide.co.uk. The principal risks and uncertainties have not changed since the date of that report.

Responsibility Statement

We confirm that to the best of our knowledge:

- a) the condensed set of Financial Statements has been prepared in accordance with FRS 104 'Interim Financial Reporting';
- b) the Interim Management Report includes a fair review of the information required by Disclosure and Transparency Rules 4.2.7R (indication of important events during the first six months, their impact on the Financial Statements and a description of principal risks and uncertainties for the remaining six months of the year); and
- c) the Interim Financial Report includes a fair review of the information required by Disclosure and Transparency Rules 4.2.8R (disclosure of related party transactions and changes therein).

By order of the Board
Henry CT Strutt
Chairman
21 June 2018

Summary of Unaudited Results*

	30 April 2018	31 October 2017 (audited)	% change
Total assets (before deduction of loans)	£426.7m	£387.8m	
Loans	£34.3m	£35.0m	
Shareholders' funds	£392.4m	£352.8m	
Net asset value per ordinary share (after deducting borrowings at fair value)	750.59p	718.89p	4.4
Share price	784.00p	690.50p	13.5
Comparative index (in sterling terms)†#			0.5
Premium/(discount) (after deducting borrowings at fair value)	4.5%	(3.9%)	
Active share (relative to S&P Global Small Cap Index)	98%	98%	

Performance since broadening of investment policy	30 April 2018	31 January 2014	% change
---	---------------	-----------------	----------

51 months from 31 January 2014

Net asset value per ordinary share (after deducting borrowings at fair value)	750.59p	436.72p	71.9
Net asset value per ordinary share (after deducting borrowings at par)	750.88p	437.17p	71.8
Share price	784.00p	405.00p	93.6
Comparative index (in sterling terms)†#			71.5

	Six months to 30 April 2018	Six months to 30 April 2017
Revenue earnings per share	(0.46p)	0.27p

	Six months to 30 April 2018	Six months to 30 April 2017	51 months from 31 January 2014
Total returns (%)#			
Net asset value per ordinary share (after deducting borrowings at fair value)	4.4	10.6	72.7
Share price	13.5	13.7	94.5
Comparative index (in sterling terms)†#	0.5	7.3	71.5

	Six months to 30 April 2018		Year to 31 October 2017	
Period's high and low	High	Low	High	Low
Share price	816.00p	690.50p	700.50p	467.75p
Net asset value per ordinary share (after deducting borrowings at fair value)	810.08p	705.82p	727.65p	519.93p
Premium/(discount) (after deducting borrowings at fair value)	5.0%	(4.6%)	(2.4%)	(13.3%)

Notes

* For a definition of terms see Glossary of Terms on page 22. † S&P Global Small Cap Index total return (in sterling terms).

Source: Thomson Reuters/Baillie Gifford and relevant underlying index providers. See disclaimer on page 23.

Past performance is not a guide to future performance.

Interim Management Report

Performance

Over the six months from 31 October 2017 to 30 April 2018, the Company's net asset value per share increased by 4.4%, which compares to a rise of 0.5% in the S&P Global Smaller Companies index*, total return in sterling terms, over the same period. The share price over the six months rose by 13.5% to 784.0p representing a premium of 4.5% to the net asset value at 30 April 2018. This compares to a discount of 3.9% at the beginning of the period. This has enabled the Company to issue new shares into natural market demand at a premium to net asset value, increasing assets by £25.1m and helping to dilute the ongoing costs for shareholders.

The broad market trends that supported the strong growth in NAV in the year to October 2017 have persisted during the current interim period. Our sense is that, on balance, stock markets would appear to be currently behaving broadly (and perhaps uncharacteristically) rationally with a focus on fundamentals and a reasonable ability to tolerate the inevitable 'noise' be it interest rates, Trump or geo-political concerns. We see this reflected in markets by greater investor willingness to differentiate between companies positioned to benefit from long term structural growth opportunities versus those businesses where the future is more challenged. We have suggested in the past that the broad range of new digital technologies and scientific advances was powering a range of exciting business opportunities. It's been pleasing to see the broader market begin to acknowledge these trends. Our sense is that these trends can be exceptionally long in duration and that the businesses they spawn are comparatively immature and undervalued compared to their ultimate potential.

Portfolio Update

Perhaps the most striking feature to impact on the portfolio over the past six months was the heightened level of acquisitive corporate activity. Three of our holdings were bid for during the period: the online fashion retailer YOOX Net-a-Porter; software company Mulesoft; and the investment advisor Financial Engines. In the case of the YOOX Net-a-Porter and Mulesoft the acquirers were larger

industry players (Richemont and Salesforce respectively) whereas Financial Engines was bid for by a private equity company. This heightened acquisition activity follows several quiet years with regard to takeovers; the last three portfolio holdings to be acquired occurred over a three year period. Whilst we recognise that some of the Company's up-and-coming holdings will inevitably carve-out a commercial proposition and uniqueness that makes them attractive to potential acquirers it's typically an outcome that we do not actively favour. Rather, we prefer our most innovative holdings to remain independent as we believe this often maximises the likelihood of a business really succeeding and ultimately increases the long term returns that can be achieved. Furthermore, we increasingly feel that the range of scalable technologies that young businesses now have access to helps relieve the growth strain that often pushed smaller businesses towards selling out to an acquirer. Time will tell but we hope the current spike in the acquisition of our holdings is a blip rather than a trend.

We remain broadly happy with the operational performance of the vast majority of the Company's holdings. Notable positive contributions were made from Ocado, GrubHub and recently listed Nucana. Ocado, the online grocery company, has made significant progress at licensing its leading automated warehouse and logistics platform to several large incumbents around the world. Our belief has been that Ocado's proposition represents the most compelling solution for selling online grocery at scale and that its hard earned experience in the UK stood it in good stead to export this to supermarket chains throughout the world. Following the period end, Ocado has also announced a sizable partnership agreement with Kroger, the second largest grocer in the US, which could see up to 20 Ocado-powered warehouses built in the US over the coming years. This is a transformational event for Ocado and a clear endorsement of how forward-thinking supermarkets are approaching changing consumer habits. GrubHub, the US online food-ordering platform, announced a strategically interesting US partnership with YUM brands, the owner of Pizza Hut, TacoBell and KFC. This partnership sees

* See disclaimer on page 23.

Past performance is not a guide to future performance.

GrubHub become YUM's exclusive national delivery partner, a development which we think is highly significant as it validates GrubHub's reach and technical expertise. Nucana, the Edinburgh-based cancer drug company, released some highly encouraging, albeit early, clinical data. In a study investigating its second-generation chemotherapy compound in a rare form of gall bladder cancer, half the patients had a clear and clinically meaningful beneficial effect from its drug. This early data provides encouraging evidence that the company's technology provides markedly superior forms of anti-cancer drugs versus the original chemotherapy agents from which they are derived.

We acquired a number of new holdings in the period including BlackLine and Jianpu Technology. BlackLine produces software which helps companies adopt continuous accounting practices. This improves compliance and reporting procedures, whilst freeing up workers for higher value added tasks. Where we are particularly excited is its potential to introduce process automation, financial analysis and forecasting for clients as well. We have been impressed by management's strategy for growth, the company's strong customer focus and its partnerships with many leading distributors. Jianpu Technology is a leading online platform that offers discovery and recommendation services for consumer finance products in China. It's the largest of its kind, working with over 2,000 financial services providers and aggregating over 170,000 products across the credit spectrum. The demand for consumer credit in China is growing rapidly whilst the industry is relatively underdeveloped and fragmented. We think Jianpu is well positioned to help address distribution issues here, and we are excited by the prospect of them developing new services with banks which could facilitate a fully digital lending experience.

We also acquired a new holding in ResTORbio, a clinical-stage biopharmaceutical company focused on selective inhibition of a critical biological pathway implicated in many age-related diseases. The targeted pathway appears to be a highly significant biological mechanism that regulates viability and

longevity of stem cells. As we age the pathway can become over-activated, a development that reduces stem cell function and impacts on the body's ability to repair and replenish. The company's initial focus is on the age related decline of the immune system which frequently manifests as a decline in the ability to combat infections, most notably infections of the respiratory tract.

By 30 April 2018 our unlisted exposure had increased to 2.5% following participation in a private funding round in Reaction Engines, a UK company that designs and manufactures very advanced heat exchangers. Thermal management is one of the most fundamental problems in engineering, underpinning the power, cost, weight and efficiency of almost every industrialised process in the world. Through pioneering advances in material science and highly intricate manufacturing, Reaction Engines has overcome many of our current limitations in this field. Its products and IP therefore have broad applicability across many existing markets and open the door for several new capabilities as well. Our other unlisted holdings at the period end were Oxford Nanopore Technologies, Spire Global and Unity Biotechnology. Following the period end, Unity Biotechnology listed on Nasdaq and a new holding was taken in Akili Interactive Labs, a company utilising technology for healthcare, the net effect has kept the unlisted exposure at 2.5% of total assets as at 31 May 2018.

The holdings in Mulesoft and YOOX Net-a-Porter were sold following the aforementioned bid approaches. We have also sold our holding in Stamps.com. The company has performed well over the several years we have held it, but we see more attractive growth opportunities elsewhere and have reallocated funds accordingly.


The principal risks and uncertainties facing the Company are set out on the inside front cover of this report.

For a definition of terms see Glossary of Terms on page 22.

Six Months Performance and Discount to Net Asset Value* (unaudited)

Six Months Performance

(figures plotted on a monthly basis and rebased to 100 at 31 October 2017)



Source: Thomson Reuters/Baillie Gifford and relevant underlying index providers.
See disclaimer on page 23.

- Share price total return
- NAV total return (after deducting borrowings at fair value)
- Comparative index*

* S&P Global Small Cap Index total return (in sterling terms). See disclaimer on page 23.

Premium/(Discount) to Net Asset Value

(plotted on a weekly basis)



Source: Thomson Reuters/Baillie Gifford. See disclaimer on page 23.

— Edinburgh Worldwide premium/(discount) (after deducting borrowings at fair value)

The premium/(discount) is the difference between Edinburgh Worldwide's quoted share price and its underlying net asset value calculated after deducting borrowings at fair value.

* For a definition of terms see Glossary of Terms on page 22.

Past performance is not a guide to future performance.


Distribution of Total Assets* (unaudited)

At 30 April 2018

Industry Analysis

Portfolio Weightings

(relative to comparative index†)




* Total assets before deduction of loans.

† S&P Global Small Cap Index. Weightings exclude industries where the Company has no exposure. See disclaimer on page 23.

Distribution of Total Assets* (unaudited)


Geographical Analysis at 30 April 2018

(31 October 2017)



Sectoral Analysis at 30 April 2018

(31 October 2017)



* Total assets before deduction of loans.

Performance of the Top 20 Holdings at 30 April 2018 (unaudited)

Name	Business	Country	Value £'000	% of total assets	Performance†	
					Absolute %	Relative %
MarketAxess	Electronic bond trading platform	USA	23,814	5.6	10.4	9.8
Alnylam Pharmaceuticals	Therapeutic gene silencing	USA	17,875	4.2	(25.2)	(25.6)
LendingTree	Online loan marketplace	USA	15,518	3.6	(14.4)	(14.9)
IPG Photonics	High-power fibre lasers	USA	11,390	2.7	(3.6)	(4.1)
Ocado	Online food retailer	UK	11,070	2.6	87.5	86.5
GrubHub	Online and mobile platform for restaurant pick-up and delivery orders	USA	10,280	2.4	59.8	58.9
Tesla, Inc	Electric cars, autonomous driving and solar energy	USA	9,579	2.2	(14.5)	(15.0)
Wayfair	Online furniture and homeware retailer	USA	8,689	2.0	(14.0)	(14.5)
Temenos Group	Banking software	Switzerland	8,407	2.0	5.6	5.0
AeroVironment	Small unmanned aircraft systems	USA	7,807	1.8	2.8	2.2
Puretech Health	IP commercialisation focused on health care	UK	7,350	1.7	16.1	15.5
IP Group	Intellectual property commercialisation	UK	7,313	1.7	(9.6)	(10.1)
Chegg	Online educational company	USA	7,146	1.7	44.3	43.5
Renishaw	Measurement and calibration equipment	UK	6,631	1.6	(4.5)	(5.1)
Baozun SPN ADR	Chinese e-commerce solution provider	China	6,458	1.5	41.3	40.5
Zillow Class C	US online real estate portal	USA	6,393	1.5	13.3	12.6
Novocure	Manufacturer of medical devices for cancer treatment	USA	6,250	1.5	22.1	21.4
Genmab	Therapeutic antibody company	Denmark	6,228	1.5	(3.3)	(3.9)
Financial Engines	Investment advisory firm	USA	6,152	1.4	19.7	19.1
Adaptimmune Therapeutics ADR	Clinical stage biopharmaceutical company	UK	5,617	1.3	56.1	55.2
			189,967	44.5		

† Absolute and relative performance has been calculated on a total return basis over the period 1 November 2017 to 30 April 2018. Absolute performance is in sterling terms; relative performance is against S&P Global Small Cap Index (in sterling terms). Source: Baillie Gifford/StatPro and relevant underlying index providers. See disclaimer on page 23.

Past performance is not a guide to future performance.

The Portfolio as at 30 April 2018 (unaudited)

Name	Business	Country	Value £'000	% of total assets
MarketAxess	Electronic bond trading platform	USA	23,814	5.6
Alnylam Pharmaceuticals	Therapeutic gene silencing	USA	17,875	4.2
LendingTree	Online loan marketplace	USA	15,518	3.6
IPG Photonics	High-power fibre lasers	USA	11,390	2.7
Ocado	Online food retailer	UK	11,070	2.6
GrubHub	Online and mobile platform for restaurant pick-up and delivery orders	USA	10,280	2.4
Tesla, Inc	Electric cars, autonomous driving and solar energy	USA	9,579	2.2
Wayfair	Online furniture and homeware retailer	USA	8,689	2.0
Temenos Group	Banking software	Switzerland	8,407	2.0
AeroVironment	Small unmanned aircraft systems	USA	7,807	1.8
Puretech Health	IP commercialisation focused on health care	UK	7,350	1.7
IP Group	Intellectual property commercialisation	UK	7,313	1.7
Chegg	Online educational company	USA	7,146	1.7
Renishaw	Measurement and calibration equipment	UK	6,631	1.6
Baozun SPN ADR	Chinese e-commerce solution provider	China	6,458	1.5
Zillow Class C	US online real estate portal	USA	6,393	1.5
Novocure	Manufacturer of medical devices for cancer treatment	USA	6,250	1.5
Genmab	Therapeutic antibody company	Denmark	6,228	1.5
Financial Engines	Investment advisory firm	USA	6,152	1.4
Adaptimmune Therapeutics ADR	Clinical stage biopharmaceutical company	UK	5,617	1.3
Genus	Animal breeding services	UK	5,570	1.3
Foundation Medicine	Develops cancer diagnostic technology	USA	5,543	1.3
Kingdee International Software	Enterprise management software	China	5,439	1.3
iRobot	Domestic and military robots	USA	5,437	1.3
InfoMart Corp	Internet platform for restaurant supplies	Japan	5,152	1.2
Galapagos	Clinical stage biotechnology company	Belgium	5,069	1.2
Xero	Cloud-based accounting software	New Zealand	4,999	1.2

Name	Business	Country	Value £'000	% of total assets
Oxford Nanopore Technologies®	Novel DNA sequencing technology	UK	4,982	1.2
Codexis	Manufacturer of custom industrial enzymes	USA	4,876	1.1
Morphosys	Therapeutic antibodies	Germany	4,839	1.1
Peptidream	Drug discovery platform	Japan	4,811	1.1
Teladoc	Telemedicine services provider	USA	4,779	1.1
MonotaRO	Online business supplies	Japan	4,416	1.0
Digital Garage	Internet business incubator	Japan	4,353	1.0
Splunk	Data diagnostics	USA	4,284	1.0
NuCana SPN ADR	An oncology-focused biotechnology company	UK	4,208	1.0
Cellectis	Biotech focused on genetic engineering	France	4,185	1.0
BlackLine	Enterprise software developer	USA	4,183	1.0
Exact Sciences	Provides non-invasive molecular tests for early cancer detection	USA	3,992	0.9
ASOS	Online fashion retailer	UK	3,975	0.9
Faro Technologies	Designs and develops measurement devices	USA	3,948	0.9
Dexcom	Real time blood glucose monitoring	USA	3,874	0.9
M3	Online medical database	Japan	3,850	0.9
STAAR Surgical	Develops and manufactures high margin visual implants	USA	3,729	0.9
Penumbra	Manufacturer of a novel blood clot extraction technology	USA	3,638	0.9
Cosmo Pharmaceuticals	Therapies for gastrointestinal diseases	Italy	3,549	0.8
Lifull (formerly Next)	Provides online property information	Japan	3,533	0.8
Trupanion	Pet health insurance provider	USA	3,527	0.8
Start Today	Internet fashion retailer	Japan	3,527	0.8
SEEK	Online recruitment portal	Australia	3,474	0.8
Victrex	High-performance thermo-plastics	UK	3,332	0.8
Xeros Technology Group	Commercial laundry manufacturer	UK	3,316	0.8
National Instruments Corp	Instrumentation equipment used in research and testing	USA	3,247	0.8
Zillow Class A	US online real estate portal	USA	3,190	0.7
Seattle Genetics	Antibody conjugates based biotechnology	USA	3,178	0.7

The Portfolio as at 30 April 2018 (unaudited)

Name	Business	Country	Value £'000	% of total assets
Rightmove	UK online property portal	UK	3,150	0.7
Mindbody CL	Business management software for the wellness sector	USA	2,732	0.6
ResTORbio	Clinical stage biopharmaceutical company	USA	2,516	0.6
Ambarella	Video compression and image processing semiconductors	USA	2,486	0.6
Basware	Software solutions for financial transactions	Finland	2,404	0.6
Pacira Pharmaceuticals	Development, commercialisation and manufacturing of proprietary pharmaceutical products	USA	2,403	0.6
Benefitfocus	Cloud-based benefits software provider	USA	2,400	0.6
Jianpu Technology ADR	Chinese consumer finance marketplace	China	2,398	0.6
Suess Microtec	Fabrication and inspection equipment	Germany	2,232	0.5
Ellie Mae	Provides technology solutions to automate mortgage origination process	USA	2,110	0.5
Aduro Biotechnology	Immunotherapy services provider	USA	2,075	0.5
Xaar	Ink jet printing technology	UK	2,051	0.5
Unity Biotechnology Inc Series B Pref.®	Biotechnology company seeking to develop anti ageing therapies	USA	2,036	0.5
Oxford Instruments	Produces advanced instrumentation equipment	UK	2,022	0.5
Stratasys	3D printer manufacturer	USA	2,011	0.5
Ceres Power Holding	Developer of fuel cells	UK	1,958	0.5
CEVA	Licenses DSP-based platforms applications to the semiconductor industry	USA	1,953	0.5
Spire Global®	Manufacturer of small, low cost satellites	USA	1,948	0.5
SDL	Language translation services	UK	1,906	0.4
Tissue Regenix	Regenerative medical devices	UK	1,820	0.4
Summit Therapeutics	Drug discovery and development	UK	1,798	0.4
Digimarc	Digital watermarking technology	USA	1,704	0.4
Dialog Semiconductor	Analogue chips for mobile phones	Germany	1,655	0.4
Reaction Engines Limited®	Advanced heat exchange company	UK	1,500	0.3

Name	Business	Country	Value £'000	% of total assets
Horizon Discovery	Customised cell lines to aid drug discovery	UK	1,466	0.3
4D Pharma	Bacteria derived novel therapeutics	UK	1,391	0.3
Ricardo	Automotive engineer	UK	1,307	0.3
China Financial Services	Small and medium-sized enterprises lending in China	China	1,260	0.3
Nanoco	Quantum dot manufacturer	UK	1,234	0.3
Catapult Group International	Sports analytics focused on optimising athlete performance	Australia	1,198	0.3
C4X Discovery Holdings	Rational drug design and optimisation	UK	1,182	0.3
Zumtobel	Commercial lighting	Austria	680	0.2
Acacia Research	Patent licensor	USA	589	0.1
Sarine Technologies	Systems for diamond grading and cutting	Singapore	494	0.1
Avacta Group	Analytical reagents and instrumentation	UK	494	0.1
Thin Film Electronics	Develops printed, rewritable memory media	Norway	439	0.1
Foamix Pharmaceuticals	Drug reformulation technology	Israel	387	0.1
Ilika	Discovery and development of materials for mass market applications	UK	373	0.1
Unity Biotechnology Inc Series C Pref.®	Biotechnology company seeking to develop anti ageing therapies	USA	298	0.1
Applied Graphene Materials	Manufactures graphene nanoplatelets	UK	287	0.1
hVIVO (formerly Retroscreen Virology)	Outsourced pre-clinical analytical services	UK	154	0.0
Velocys	Gas to liquid technology	UK	52	0.0
GI Dynamics	Develops and markets medical devices	Australia	17	0.0
Ensogo	South East Asian e-commerce	Australia	0	0.0
China Lumena New Materials	Mines, processes and manufactures natural thenardite products	China	0	0.0
Total equities			402,541	94.3
Net current assets			24,197	5.7
Total assets at fair value (before deduction of loans)			426,738	100.0

® Denotes unlisted equity.

Income Statement (unaudited)

	For the six months ended 30 April 2018			For the six months ended 30 April 2017			For the year ended 31 October 2017 (audited)		
	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000
Gains on sales of investments	–	14,257	14,257	–	8,560	8,560	–	13,658	13,658
Movements in investment holding gains and (losses)	–	1,220	1,220	–	19,937	19,937	–	71,923	71,923
Currency gains	–	501	501	–	851	851	–	824	824
Income from investments and interest receivable	578	–	578	563	–	563	1,268	–	1,268
Investment management fee (note 3)	(315)	(945)	(1,260)	(250)	(750)	(1,000)	(535)	(1,606)	(2,141)
Other administrative expenses	(341)	–	(341)	(266)	–	(266)	(513)	–	(513)
Net return before finance costs and taxation	(78)	15,033	14,955	47	28,598	28,645	220	84,799	85,019
Finance costs of borrowings	(119)	(357)	(476)	(126)	(378)	(504)	(250)	(749)	(999)
Net return on ordinary activities before taxation	(197)	14,676	14,479	(79)	28,220	28,141	(30)	84,050	84,020
Tax on ordinary activities	(35)	–	(35)	212	28	240	179	28	207
Net return on ordinary activities after taxation	(232)	14,676	14,444	133	28,248	28,381	149	84,078	84,227
Net return per ordinary share (note 4)	(0.46p)	29.48p	29.02p	0.27p	57.64p	57.91p	0.30p	171.58p	171.88p

The total column of this Statement represents the profit and loss account of the Company. The supplementary revenue and capital columns are prepared under guidance published by the Association of Investment Companies.

All revenue and capital items in this Statement derive from continuing operations.

A Statement of Comprehensive Income is not required as the Company does not have any other comprehensive income and the net return on ordinary activities after taxation is both the profit and comprehensive income for the period.

Balance Sheet (unaudited)

	At 30 April 2018 £'000	At 31 October 2017 (audited) £'000
Fixed assets		
Investments held at fair value through profit or loss (note 6)	402,541	383,846
Current assets		
Debtors	2,689	102
Cash and cash equivalents	27,222	4,686
	29,911	4,788
Creditors		
Amounts falling due within one year	(5,714)	(771)
Net current assets	24,197	4,017
Total assets less current liabilities	426,738	387,863
Creditors		
Amounts falling due after more than one year (note 7)	(34,332)	(35,024)
Net assets	392,406	352,839
Capital and reserves		
Share capital	2,613	2,450
Share premium account	107,140	82,180
Special reserve	35,220	35,220
Capital reserve	246,696	232,020
Revenue reserve	737	969
Shareholders' funds	392,406	352,839
Net asset value per ordinary share (after deducting borrowings at fair value) (note 7)	750.59p	718.89p
Net asset value per ordinary share (after deducting borrowings at par)	750.88p	720.02p
Ordinary shares in issue (note 8)	52,259,319	49,004,319

Statement of Changes in Equity (unaudited)

For the six months ended 30 April 2018

	Share capital £'000	Share premium account £'000	Special reserve £'000	Capital reserve* £'000	Revenue reserve £'000	Shareholders' funds £'000
Shareholders' funds at 1 November 2017	2,450	82,180	35,220	232,020	969	352,839
Ordinary shares issued (note 8)	163	24,960	–	–	–	25,123
Net return on ordinary activities after taxation	–	–	–	14,676	(232)	14,444
Shareholders' funds at 30 April 2018	2,613	107,140	35,220	246,696	737	392,406

For the six months ended 30 April 2017

	Share capital £'000	Share premium account £'000	Special reserve £'000	Capital reserve* £'000	Revenue reserve £'000	Shareholders' funds £'000
Shareholders' funds at 1 November 2016	2,450	82,180	35,220	147,942	820	268,612
Net return on ordinary activities after taxation	–	–	–	28,248	133	28,381
Shareholders' funds at 30 April 2017	2,450	82,180	35,220	176,190	953	296,993

* The Capital Reserve as at 30 April 2018 includes investment holding gains of £123,623,000 (30 April 2017 – gains of £70,416,000).

Condensed Cash Flow Statement (unaudited)

	Six months to 30 April 2018 £'000	Six months to 30 April 2017 £'000
Cash flows from operating activities		
Net return on ordinary activities before taxation*	14,479	28,141
Net gains on investments	(15,477)	(28,497)
Currency gains	(501)	(851)
Finance costs of borrowings	476	504
Overseas tax (incurred)/repaid	(27)	248
Changes in debtors and creditors	5	(7)
Cash from operations	(1,045)	(462)
Interest paid	(476)	(510)
Net cash outflow from operating activities	(1,521)	(972)
Net cash (outflow)/inflow from investing activities	(293)	3,921
Ordinary shares issued	24,541	–
Net cash inflow from financing activities	24,541	–
Increase in cash and cash equivalents	22,727	2,949
Exchange movements	(191)	(858)
Cash and cash equivalents at start of period	4,686	13,244
Cash and cash equivalents at end of period†	27,222	15,335

* Cash from operations includes dividends received in the period of £505,000 (30 April 2017 – £439,000) and interest received of £24,000 (30 April 2017 – £70,000).

† Cash and cash equivalents represent cash at bank and short term money market deposits repayable on demand.

Notes to the Condensed Financial Statements (unaudited)

- 1 The condensed Financial Statements for the six months to 30 April 2018 comprise the statements set out on pages 12 to 16 together with the related notes on pages 17 to 19. They have been prepared in accordance with FRS 104 'Interim Financial Reporting' and the AIC's Statement of Recommended Practice issued in November 2014, updated in January 2017 with consequential amendments, and have not been audited or reviewed by the Auditor pursuant to the Auditing Practices Board Guidance on 'Review of Interim Financial Information'. The Financial Statements for the six months to 30 April 2018 have been prepared on the basis of the same accounting policies as set out in the Company's Annual Report and Financial Statements at 31 October 2017.

Going Concern

Having considered the nature of the Company's principal risks and uncertainties, as set out on the inside front cover, together with its current position, investment objective and policy, its assets and liabilities, and projected income and expenditure, together with the Company's dividend policy, it is the Directors' opinion that the Company has adequate resources to continue in operational existence for the foreseeable future. The Company's assets, the majority of which are investments in quoted securities which are readily realisable, exceed its liabilities significantly. All borrowings require the prior approval of the Board. Gearing levels and compliance with borrowing covenants are reviewed by the Board on a regular basis. Accordingly, the Directors consider it appropriate to adopt the going concern basis of accounting in preparing these Financial Statements and confirm that they are not aware of any material uncertainties which may affect the Company's ability to continue to do so over a period of at least twelve months from the date of approval of these Financial Statements.

- 2 The financial information contained within this Interim Financial Report does not constitute statutory accounts as defined in sections 434 to 436 of the Companies Act 2006. The financial information for the year ended 31 October 2017 has been extracted from the statutory accounts which have been filed with the Registrar of Companies. The Auditor's Report on those accounts was not qualified, did not include a reference to any matters to which the Auditors drew attention by way of emphasis without qualifying their report, and did not contain a statement under sections 498(2) or (3) of the Companies Act 2006.
- 3 Baillie Gifford & Co Limited, a wholly owned subsidiary of Baillie Gifford & Co, has been appointed by the Company as its Alternative Investment Fund Manager and Company Secretary. The investment management function has been delegated to Baillie Gifford & Co. The management agreement is terminable on not less than three months' notice. The annual management fee is 0.95% on the first £50m of net assets, 0.65% on the next £200m of net assets and 0.55% on the remaining net assets. Management fees are calculated and payable quarterly.

	Six months to 30 April 2018 £'000	Six months to 30 April 2017 £'000	Year to 31 October 2017 (audited) £'000
4 Net return per ordinary share			
Revenue return on ordinary activities after taxation	(232)	133	149
Capital return on ordinary activities after taxation	14,676	28,248	84,078
Total return	14,444	28,381	84,227
Weighted average number of ordinary shares in issue	49,778,352	49,004,319	49,004,319

Net return per ordinary share is based on the above totals of revenue and capital and the weighted average number of ordinary shares in issue during each period. There are no dilutive or potentially dilutive shares in issue.

Notes to the Condensed Financial Statements (unaudited)

5 No interim dividend has been declared.

6 Fair Value Hierarchy

The fair value hierarchy used to analyse the basis on which the fair values of financial instruments held at fair value through the profit or loss account are measured is described below. Fair value measurements are categorised on the basis of the lowest level input that is significant to the fair value measurement.

Level 1 – using unadjusted quoted prices for identical instruments in an active market;

Level 2 – using inputs, other than quoted prices included within Level 1, that are directly or indirectly observable (based on market data); and

Level 3 – using inputs that are unobservable (for which market data is unavailable).

An analysis of the Company's financial asset investments based on the fair value hierarchy described above is shown below.

Investments held at fair value through profit or loss

	Level 1 £'000	Level 2 £'000	Level 3 £'000	Total £'000
As at 30 April 2018				
Listed equities	391,777	–	–	391,777
Unlisted equities	–	–	10,764	10,764
Total financial asset investments	391,777	–	10,764	402,541
	Level 1 £'000	Level 2 £'000	Level 3 £'000	Total £'000
As at 31 October 2017				
Listed equities	375,905	–	–	375,905
Unlisted equities	–	–	7,941	7,941
Total financial asset investments	375,905	–	7,941	383,846

There have been no transfers between levels of the fair value hierarchy during the period. The fair value of listed investments is either bid price or, depending on the convention of the exchange on which the investment is listed, last traded price. Listed investments are categorised as Level 1 if they are valued using unadjusted quoted prices for identical instruments in an active market and as Level 2 if they do not meet all these criteria but are, nonetheless, valued using market data. Unlisted investments are valued at fair value by the Directors following a detailed review and appropriate challenge of the valuations proposed by the Managers. The Managers' unlisted investment policy applies methodologies consistent with the International Private Equity and Venture Capital Valuation guidelines ('IPEV'). These methodologies can be categorised as follows: (a) market approach (price of recent investment, multiples, industry valuation benchmarks and available market prices); (b) income approach (discounted cash flows); and (c) replacement cost approach (net assets). The Company's holdings in unlisted investments are categorised as Level 3 as unobservable data is a significant input to their fair value measurements.

- 7** At 30 April 2018 creditors falling due after more than one year comprise borrowings of £34,332,000 (31 October 2017 – £35,024,000) drawn down under a five year fixed rate facility with National Australia Bank Limited which expires on 30 September 2019. The loans drawn down consisted €9.4m, US\$25.6m and £7.5m at 30 April 2018 and 31 October 2017.
The fair value of the bank loans at 30 April 2018 was £34,484,000 (31 October 2017 – £35,574,000).
- 8** The Company has the authority to issue shares/sell treasury shares at a premium to net asset value as well as to buy back shares at a discount to net asset value. In the six months to 30 April 2018, 3,255,000 ordinary shares (year to 31 October 2017 – nil) were issued at a premium to net asset value raising net proceeds of £25,123,000 (year to 31 October 2017 – nil).
In the six months to 30 April 2018 no ordinary shares were bought back therefore the Company's authority remains unchanged at 7,345,747 ordinary shares.
- 9** During the period the Company incurred transaction costs on purchases of investments of £12,000 (30 April 2017 – £9,000; 31 October 2017 – £23,000) and transaction costs on sales of £13,000 (30 April 2017 – £7,000; 31 October 2017 – £23,000).

10 Related Party Transactions

There have been no transactions with related parties during the first six months of the current financial year that have materially affected the financial position or the performance of the Company during that period and there have been no changes in the related party transactions described in the last Annual Report and Financial Statements that could have had such an effect on the Company during that period.

None of the views expressed in this document should be construed as advice to buy or sell a particular investment.

Further Shareholder Information

Edinburgh Worldwide's shares are traded on the London Stock Exchange. They can be bought through a stockbroker, by asking a professional adviser to do so, or through the Baillie Gifford savings vehicles.

Baillie Gifford's Investment Trust Share Plan

You can invest a minimum of £250 or from £30 per month. The plan is designed to be a cost-effective way of saving on a regular or lump sum basis.

Baillie Gifford's Investment Trust ISA

You can invest in a tax efficient way by investing a minimum of £2,000 or from £100 per month or by transferring an ISA with a value of at least £2,000 from your existing manager.

Baillie Gifford's Children's Savings Plan

A cost-effective plan tailored especially to meet the requirements to save for children. You can invest a minimum of £100 or from £25 per month.

Online Management Service

You can open and manage your Share Plan, Children's Savings Plan* and/or ISA online, through our secure Online Management Service ('OMS') which can be accessed through the Baillie Gifford website at www.bailliegifford.com/oms. As well as being able to view the details of your plan online, the service also allows you to:

- obtain current valuations;
- make lump sum investments, except where there is more than one holder;
- sell part or all of your holdings, except where there is more than one holder;
- switch between investment trusts, except where there is more than one holder; and
- update certain personal details e.g. address and telephone number.

* Please note that a Bare Trust cannot be opened via OMS. A Bare Trust application form must be completed.

The information about the ISA, Share Plan and Children's Savings Plan has been approved by Baillie Gifford Savings Management Limited ('BGSM'). BGSM is the Manager of The Baillie

Gifford Investment Trust Share Plan, The Baillie Gifford Children's Savings Plan and The Baillie Gifford Investment Trust ISA. BGSM is wholly owned by Baillie Gifford & Co. Both are authorised and regulated by the Financial Conduct Authority and both are based at Calton Square, 1 Greenside Row, Edinburgh EH1 3AN. Baillie Gifford only provides information about its products and does not provide investment advice.

Client Relations Team Contact Details

You can contact the Baillie Gifford Client Relations Team by telephone (your call may be recorded for training or monitoring purposes), email, fax or post. See contact details in the 'Further Information' box on the back cover.

Share Register Enquiries

Computershare Investor Services PLC maintains the share register on behalf of the Company. In the event of queries regarding shares registered in your own name, please contact the Registrars on 0370 707 1643.

Automatic Exchange of Information

In order to fulfil its obligations under UK tax legislation relating to the automatic exchange of information, Edinburgh Worldwide Investment Trust plc is required to collect and report certain information about certain shareholders.

The legislation requires investment trust companies to provide personal information to HMRC on certain investors who purchase shares in investment trusts. Accordingly, Edinburgh Worldwide Investment Trust plc will have to provide information annually to the local tax authority on the tax residencies of a number of non-UK based certificated shareholders and corporate entities.

Shareholders, excluding those whose shares are held in CREST, who come on to the share register will be sent a certification form for the purposes of collecting this information.

For further information, please see HMRC's Quick Guide: Automatic Exchange of Information – information for account holders

<https://www.gov.uk/government/publications/exchange-of-information-account-holders>.

Further Shareholder Information

Risk Warnings

Past performance is not a guide to future performance.

Edinburgh Worldwide is a UK listed company. The value of its shares and any income from them can fall as well as rise and you may not get back the amount invested.

Edinburgh Worldwide invests in overseas securities, changes in the rates of exchange may also cause the value of your investment (and any income it may pay) to go down or up.

Edinburgh Worldwide has borrowed money to make further investments (sometimes known as 'gearing' or 'leverage'). The risk is that when this money is repaid by the Company, the value of the investments may not be enough to cover the borrowing and interest costs, and the Company will make a loss. If the Company's investments fall in value, any invested borrowings will increase the amount of this loss.

Edinburgh Worldwide can buy back its own shares. The risks from borrowing, referred to above, are increased when the Company buys back its own shares.

Market values for securities which have become difficult to trade may not be readily available and there can be no assurance that any value assigned to such securities will accurately reflect the price the Company might receive upon their sale.

Edinburgh Worldwide has investments in smaller, immature companies which are generally considered higher risk as changes in their share prices may be greater and the shares may be harder to sell. Smaller, immature companies may do less well in periods of unfavourable economic conditions.

Edinburgh Worldwide's risk could be increased by its investment in unlisted investments. These assets may be more difficult to buy or sell, so changes in their prices may be greater.

Edinburgh Worldwide can make use of derivatives which may impact on its performance.

Edinburgh Worldwide charges 75% of the investment management fee and 75% of borrowing costs to capital which reduces the capital value. Also, where income is low, the remaining expenses may be greater than the total income received, meaning the Company may not pay a dividend and the capital value would be further reduced.

The aim of Edinburgh Worldwide is to achieve capital growth. You should not expect a significant, or steady, annual income from the Company.

You should note that tax rates and reliefs may change at any time and their value depends on your circumstances.

Details of other risks that apply to investment in the savings vehicles shown on page 20 are contained in the product brochures. Further details of the risks associated with investing in the Company, including how charges are applied, can be found at www.edinburghworldwide.co.uk, or by calling Baillie Gifford on 0800 917 2112.

Edinburgh Worldwide is a UK public listed company and as such complies with the requirements of the UK Listing Authority and is not authorised or regulated by the Financial Conduct Authority.

The information and opinions expressed within this Interim Financial Report are subject to change without notice.

This information has been issued and approved by Baillie Gifford & Co Limited and does not in any way constitute investment advice.

The staff of Baillie Gifford & Co and Edinburgh Worldwide's Directors may hold shares in Edinburgh Worldwide and may buy and sell such shares from time to time.

Glossary of Terms

Total Assets

The total value of all assets held less all liabilities (other than liabilities in the form of borrowings).

Shareholders' Funds and Net Asset Value

Shareholders' Funds is the value of all assets held less all liabilities, with borrowings deducted at book cost. Net Asset Value (NAV) is the value of all assets held less all liabilities, with borrowings deducted at either fair value or par value as described below. Per share amounts are calculated by dividing the relevant figure by the number of ordinary shares in issue.

Borrowings at Fair Value

Borrowings are valued at an estimate of their market worth.

Borrowings at Par Value

Borrowings are valued at nominal par value (book cost).

Net Liquid Assets

Net liquid assets comprise current assets less current liabilities (excluding borrowings).

Discount/Premium

As stockmarkets and share prices vary, an investment trust's share price is rarely the same as its NAV. When the share price is lower than the NAV per share it is said to be trading at a discount. The size of the discount is calculated by subtracting the share price from the NAV per share and is usually expressed as a percentage of the NAV per share. If the share price is higher than the NAV per share, this situation is called a premium.

Total Return

The total return is the return to shareholders after reinvesting the dividend on the date that the share price goes ex-dividend.

Ongoing Charges

The total expenses (excluding borrowing costs) incurred by the Company as a percentage of the average net asset value (with debt at fair value).

Active Share

Active share, a measure of how actively a portfolio is managed, is the percentage of the portfolio that differs from its comparative index. It is calculated by deducting from 100 the percentage of the portfolio that overlaps with the comparative index. An active share of 100 indicates no overlap with the index and an active share of zero indicates a portfolio that tracks the index.

Gearing

At its simplest, gearing is borrowing. Just like any other public company, an investment trust can borrow money to invest in additional investments for its portfolio. The effect of the borrowing on the shareholders' assets is called 'gearing'. If the Company's assets grow, the shareholders' assets grow proportionately more because the debt remains the same. But if the value of the Company's assets falls, the situation is reversed. Gearing can therefore enhance performance in rising markets but can adversely impact performance in falling markets.

Potential gearing is the Company's borrowings expressed as a percentage of shareholders' funds.

Invested gearing is the Company's borrowings at par less cash and brokers' balances expressed as a percentage of shareholders' funds.

Leverage

For the purposes of the Alternative Investment Fund Managers Directive, leverage is any method which increases the Company's exposure, including the borrowing of cash and the use of derivatives. It is expressed as a ratio between the Company's exposure and its net asset value and can be calculated on a gross and a commitment method. Under the gross method, exposure represents the sum of the Company's positions after the deduction of sterling cash balances, without taking into account any hedging and netting arrangements. Under the commitment method, exposure is calculated without the deduction of sterling cash balances and after certain hedging and netting positions are offset against each other.

Third Party Data Provider Disclaimer

No third party data provider ('Provider') makes any warranty, express or implied, as to the accuracy, completeness or timeliness of the data contained herewith nor as to the results to be obtained by recipients of the data. No Provider shall in any way be liable to any recipient of the data for any inaccuracies, errors or omissions in the index data included in this document, regardless of cause, or for any damages (whether direct or indirect) resulting therefrom.

No Provider has any obligation to update, modify or amend the data or to otherwise notify a recipient thereof in the event that any matter stated herein changes or subsequently becomes inaccurate.

Without limiting the foregoing, no Provider shall have any liability whatsoever to you, whether in contract (including under an indemnity), in tort (including negligence), under a warranty, under statute or otherwise, in respect of any loss or damage suffered by you as a result of or in connection with any opinions, recommendations, forecasts, judgments, or any other conclusions, or any course of action determined, by you or any third party, whether or not based on the content, information or materials contained herein.

S&P Index Data

The S&P Global Small Cap Index ('Index') is a product of S&P Dow Jones Indices LLC, a division of S&P Global, or its affiliates ('SPDJI'). Standard & Poor's® and S&P® are registered trademarks of Standard & Poor's Financial Services LLC, a division of S&P Global ('S&P'); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC ('Dow Jones'). Neither S&P Dow Jones Indices LLC, Dow Jones Trademark Holdings LLC, their affiliates

nor their third party licensors make any representation or warranty, express or implied, as to the ability of any index to accurately represent the asset class or market sector that it purports to represent and neither S&P Dow Jones Indices LLC, Dow Jones Trademark Holdings LLC, their affiliates nor their third party licensors shall have any liability for any errors, omissions, or interruptions of any index or the data included therein.

Directors

Chairman:
HCT Strutt

DAJ Cameron
WJ Ducas
H James
MIG Wilson

Alternative Investment Fund Managers, Secretaries and Registered Office

Baillie Gifford & Co Limited
Calton Square
1 Greenside Row
Edinburgh
EH1 3AN
Tel: 0131 275 2000
www.bailliegifford.com

Registrar

Computershare
Investor Services PLC
The Pavilions
Bridgwater Road
Bristol BS99 6ZZ
Tel: 0370 707 1643

Depository

The Bank of New York Mellon
(International) Limited
1 Canada Square
London
E14 5AL

Company Broker

Numis Securities Limited
The London Stock
Exchange Building
10 Paternoster Square
London
EC4M 7LT

Independent Auditor

Ernst & Young LLP
Atria One
144 Morrison Street
Edinburgh
EH3 8EX

Company Details

www.edinburghworldwide.co.uk
Company Registration
No. SC184775
ISIN GB0002916335
Sedol 0291633
Ticker EWI

Legal Entity Identifier:
213800JUA8RKIDDLH380

Further Information

Client Relations Team
Baillie Gifford Savings
Management Limited
Calton Square
1 Greenside Row
Edinburgh
EH1 3AN
Tel: 0800 917 2112
E-mail:
trustenquiries@bailliegifford.com
Fax: 0131 275 3955